Table 2 Characteristics of Graft Source and Conditioning Regimes Used
From: Stem Cell Transplantation for Primary Immunodeficiency Disease: Experience of a Singapore Hospital
Patient | Age at SCT (mo) | Time From Diagnosis to SCT (mo) | Source | Graft Type | HLA-Identity | Conditioning Regimen | GVHD Prophylaxis | NC × 107/kg Infused | CD34 × 106/kg Infused |
|---|---|---|---|---|---|---|---|---|---|
1 | 56 | 4 | BM | MRD | 6/6 | BU 16.0 mg/kg; CY 200 mg/kg | CsA + MTX | 23.7 | 4.8 |
2 | 20 | 8 | PB | MRD | 6/6 | BU 16.0 mg/kg; CY 200 mg/kg | CsA +MTX | 22.1 | 5.54 |
3 | 5 | 1 | CB | MUD | 6/6 | CY 100 mg/kg; FLU 150 mg/m2 | CsA +MTX | 10.1 | 2.43 |
4 | 204 | 136 | CB | MUD | 5/6 | BU 12.8 mg/kg; FLU 150 mg/m2; ATG 8 mg/kg | CsA + Pred + MMF | 4.78 | 0.15 |
5 | 32 | 6 | CB | MUD | 4/6 | BU 8.0 mg/kg; ATG 6.0 mg/kg | CsA + Pred | 21.8 | 0.44 |
6 | 71 | 49 | CB | MUD | 5/6 | BU 16 mg/kg; CY 200 mg/kg; ATG 4.5 mg/kg | CsA + MTX + Pred | 6.36 | 0.24 |
7(first SCT) | 97 | 53 | PB | MUD | 6/6 | BU 16 mg/kg; CY 200 mg/kg; ATG 5 mg/kg | CsA + MTX + Pred | 42.7 | 3.22 |
7 (second SCT) | 100 | 55 | BM | MUD | 6/6 | CY 50 mg/kg; ATGequine 90 mg/kg; rituximab 375 mg/m2 | CSA + Pred + MMF | 46.9 | 2.81 |